Loading...
Market
What will be the outcome of regulatory discussions for Duvakitug Phase 3 trial by December 31, 2025?
2
Resolution / Starting Odds
Approved • 33%
Rejected • 33%
Request for more data • 34%
Official announcements from regulatory bodies like the FDA or EMA
Story
Teva and Sanofi's Duvakitug Shows Promise in Phase 2b Trial for IBD, Shares Surge
Dec 17, 2024, 03:45 PM
Teva Pharmaceutical Industries and Sanofi have announced positive results from a Phase 2b clinical trial named RELIEVE UCCD for their drug, Duvakitug, which targets ulcerative colitis and Crohn's disease. The trial showed that Duvakitug met its primary endpoints, with 36.2% of ulcerative colitis patients on a low dose and 47.8% on a high dose achieving clinical remission, compared to 20.45% on placebo. For Crohn's disease, 26.1% of patients on a low dose and 47.8% on a high dose achieved an endoscopic response, compared to 13% on placebo. The drug was well tolerated with no safety signals identified. Following these results, Teva's shares surged by nearly 20%, while Sanofi's shares climbed by almost 5%. The companies plan to initiate Phase 3 development pending regulatory discussions.
View original story
Similar markets
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Phase 2 trial completion • 25%
Phase 3 trial initiation • 25%
Regulatory approval in any region • 25%
No significant milestone • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Approved • 25%
Approved with Conditions • 25%
Not Approved • 25%
Decision Delayed • 25%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Approval recommended • 25%
Approval not recommended • 25%
No consensus • 25%
Meeting postponed • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Approved • 25%
Not Approved • 25%
Conditional Approval • 25%
Approval Delayed • 25%